Walleye Capital
BBIO icon

Walleye Capital’s BridgeBio Pharma BBIO Stock Holding History

Walleye Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$958K Sell
12,900
-2,100
-14% -$152K ﹤0.01% 2115
2025
Q4 		$1.15M Buy
15,000
+8,500
+131% +$558K ﹤0.01% 2331
2025
Q3 		$338K Sell
6,500
-7,200
-53% -$351K ﹤0.01% 2914
2025
Q2 		$592K Buy
13,700
+5,600
+69% +$204K ﹤0.01% 2495
2025
Q1 		$280K Sell
8,100
-15,000
-65% -$506K ﹤0.01% 3006
2024
Q4 		$634K Buy
23,100
+2,400
+12% +$62K ﹤0.01% 2794
2024
Q3 		$527K Sell
20,700
-7,700
-27% -$202K ﹤0.01% 3251
2024
Q2 		$719K Buy
28,400
+21,900
+337% +$599K ﹤0.01% 3159
2024
Q1 		$201K Buy
+6,500
New +$221K ﹤0.01% 3975
2023
Q4 		– Sell
-10,900
Closed -$287K – 4932
2023
Q3 		$287K Buy
10,900
+8,400
+336% +$238K ﹤0.01% 3274
2023
Q2 		$43K Sell
2,500
-3,400
-58% -$51.2K ﹤0.01% 3665
2023
Q1 		$97.8K Buy
+5,900
New +$68.8K ﹤0.01% 2940

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's BBIO Position: Q1 2026 in Review

Walleye Capital increased its BridgeBio Pharma (BBIO) stake by 4,623% in Q1 2026, buying an estimated $16.2M and bringing the position to 228,593 shares worth $17M. The position accounts for 0.07% of the portfolio, ranked #236.

Walleye Capital first reported a position in BBIO in Q1 2021 and has held it in 12 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Walleye Capital held 228,593 shares of BridgeBio Pharma worth $17M as of Q1 2026.
  • Walleye Capital bought 223,753 BridgeBio Pharma shares in Q1 2026, an estimated $16.2M.
  • BridgeBio Pharma made up 0.07% of Walleye Capital's portfolio in Q1 2026, its #236 holding.
  • Walleye Capital first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 12 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.